ATYR

Conviction 5HealthcareScan · Thu, Jun 25, 2026

ATYR$0.5546-1.23%

ResistanceSupportVol 14Insider buy

Vol MA14 1.88M

Mar 26Apr 14May 1May 19Jun 8Jun 25

aTYR PHARMA INCBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.atyrpharma.com ↗

Price0.5546

Change-1.23%

Gap+1.51%

Rel volume1.02×

Avg volume2.56M

Avg $ vol1.29M

SMA 200.4895

SMA 500.6290

SMA 2000.8803

Price vs 50-11.83%

Price vs 200-37.00%

MA stackbearish

50/200 cross—

Supertrenddown · 0.5945

RSI (14)53

MACD hist0.02

MACD cross—

Stoch %K / %D75 / 78

ADX (14)22

+DI / −DI24 / 15

RSI divergence—

MACD divergence—

ATR %+10.18%

ADR %9.28%

52w high6.61

52w low0.3959

From 52w high-91.61%

Above 52w low+40.09%

New 52w highNo

SqueezeOff

Bollinger width33.02%

%B0.90

Donchian pos74.69%

Donchian high0.5948

Donchian low0.4360

AVWAP (52w high)1.60

vs AVWAP high-65.36%

AVWAP (52w low)0.4994

vs AVWAP low+11.06%

OBV trendUp

Chaikin MF (20)-0.15

Today vs 20d1.02×

Avg vol (14d)1.88M

Avg vol (20d)2.56M

Avg $ vol (20d)1.29M

Market cap54.38M

RS 3m (vs SPY)-41.15%

RS 6m (vs SPY)-32.87%

RS line new highNo

Trend template1/8

Technical rank31.5

1 week+19.81%

1 month+14.52%

3 months-30.61%

6 months-23.60%

1 year-89.56%

YTD-26.94%

P/E-0.73

P/B0.94

P/S286.21

P/FCF-0.88

EPS-0.8000

Div yield—

ROE-127.94%

ROA-93.05%

Debt/Eq0.10

Current5.78

EV/EBITDA-0.65

Gross margin—

Net margin—

Rev growth-19.15%

EPS growth-15.77%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value50.17M

Revenue190K

Net income-10.79M

Gross profit—

Free cash flow-62.06M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out98.05M

Employees58

ListedThu, May 7, 2015

Free float96.43M

Float %98.4%

Short interest20.19M

Days to cover5.0d

Short volume39.8%

Squeeze score65 / 100

Next earningsThu, Aug 6, 2026 (42d)

EPS forecast−$0.15 · 2 est

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction5 / 100

Pattern quality—

Tech rank31.5 / 100

Group rank—

Status laneNo active setup

Setup direction—

Pattern family

Resistance0.9625

Support0.4155

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ATYR

All disclosures →

No recent disclosed trades by Congress in ATYR. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ATYR · 7 buys

Insider	Side	Shares	Value	Traded	Filed
SCHIMMEL PAUL Director · Common Stock · 2026-05-27	Other	—	—	2026-05-27	2026-05-28
SCHIMMEL PAUL Director · Common Stock · 2026-05-27	Buy	100K	$50K	2026-05-27	2026-05-28
Lucas Svetlana Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
Coughlin Timothy Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
BENEVICH ERIC Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
SCHIMMEL PAUL Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
Zaknoen Sara Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
Gross Jane A Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13

SEC filings

EDGAR filings in ATYR · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.